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Original Article

Polymorphisms of Fractalkine Receptor CX3CR1 Gene in Patients
with Symptomatic and Asymptomatic Carotid Artery Stenosis
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Aim: The chemokine fractalikine is expressed in vascular endothelium, exerting a pro-atherogenic
effect. Two single-nucleotide polymorphisms of the CX3CR1 gene (T280M and V249I) affect fractalkine receptor expression and function. We aimed to assess the prevalence of CX3CR1 polymorphisms and the association with ischemic cerebrovascular attacks in a cohort of carotid atheromatous
disease patients and age-matched controls.
Methods: Using PCR-RFLP, we analyzed allelotypes for T280M and V249I in 150 patients with and
151 controls without carotid atherosclerosis assessed using carotid duplex ultrasound; the subjects
were patients admitted for any reason to a tertiary hospital. Genotype data were compared with
modifiable risk factors for cerebrovascular disease and the reason for admission, using ischemic stroke
as an endpoint. Stroke types associated with carotid atherosclerosis were analysed separately.
Results: The M280 allelic frequency was lower among carotid atherosclerosis patients than controls
(0.15 versus 0.23, adjusted OR 0.47, 95% CI 0.30−0.74). Absence of M280 allele was an independent factor associated with carotid atherosclerosis (OR 3.70, 95% CI 1.92−7.14), stronger than
hypertension, dyslipidemia, diabetes and cigarette smoking. The I249 allele was also under-represented in carotid atherosclerosis; this was not statistically significant. T280M and V249I genotypes
were not associated with admission due to ischemic stroke of the large vessel subtype (TOAST classification, 73 episodes), whereas carotid atherosclerosis, previous ischemic event, age, hypertension,
diabetes, hyperlipidemia and cigarette smoking were all independently associated.
Conclusions: The M280 fractalkine receptor gene allele is associated with a lower risk of carotid atheromatous disease, independent from the modifiable cerebrovascular risk factors.
J Atheroscler Thromb, 2009; 16:604-610.
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Introduction
Cerebrovascular attacks (CVAs), a leading cause
of mortality and morbidity in the developed world,
consist of ischemic events in more than 80% of
cases 1). Atherosclerosis plays a cardinal role, either by
producing an embolus from a ruptured plaque or by
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occlusion of cerebral vessels from plaque formation in
situ 2). Atherosclerosis is an inflammatory process that
entails interactive participation of inflammatory cells
with vascular endothelium, smooth muscle cells, and
fibroblasts 3). Chemokines mediate the accumulation
of inflammatory cells in atherosclerotic plaque 4) and
their effect has been associated with atherosclerosis
progression in both functional and genetic studies 5, 6).
Fractalkine is a chemokine expressed in both soluble and transmembrane forms 7). Soluble fractalkine
is a potent chemoattractant for monocytes and T cells
and the transmembrane form is expressed on endothelial cells under stimulation by proinflammatory molecules 8). Detection of fractalkine in human atheroscle-
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rotic lesions and its absence in normal arteries supported its role in atherosclerosis 9). Two single-nucleotide polymorphisms (SNPs) are in linkage disequilibrium within the coding region of the CX3CR1 gene
(which encodes for the fractalike receptor) resulting
in the substitution of valine by isoleukine (V249I)
and threonine by methionine (T280M), respectively 10).
The 280M minor allele has been independently associated with a decreased risk of coronary artery disease
(CAD) 11-13). Data on the role of the 249I minor polymorphic allele are contradictory: both negative 14, 15)
and positive 12) associations with CAD risk have been
reported, whereas other studies did not reveal any
association 11, 13).
Data on the role of CX3CR1 polymorphisms in
cerebrovascular disease are more limited and conflicting. The 280M allele has been independently associated with a reduced risk of internal carotid artery (ICA)
occlusive stenosis, whereas the 249I allele has been
found more commonly among people with hard
carotid atheromatous plaques (which are considered
more stable than the soft plaque) 16). In another study,
homozygosity for the 280M allele, but not the 249I,
was associated with decreased intima-media thickness
of the common carotid artery 17). In contrast, the rare
homozygosity of the 280M and, less so, the 249I allele
has been independently associated with an increased
risk of brain infarction in a large case-control study 18),
whereas lack of any association between CX3CR1 SNPs
and cerebrovascular disease has also been reported in
other population settings 19).
To further elucidate the role of CX3CR1 gene
polymorphisms in ischemic cerebrovascular disease,
we performed genotype analysis in a cohort of patients
with known carotid atheromatous disease and agematched controls without clinically detectable carotid
atherosclerosis. We also compared genotype data against
the history of cerebrovascular attacks (strokes and/or
TIAs) and the conventional epidemiologic risk factors
for cerebrovascular disease among study subjects.
Materials and Methods
The study population consisted of all adults
admitted, for any reason, to a general medicine ward
of a teaching hospital in Athens during a 1-year period
(September 2003−August 2004), who underwent a
carotid duplex ultrasound or had one available for the
6 months prior to hospitalization. For patients admitted with stroke, carotid ultrasound was performed as
part of the routine work-up during hospitalization. All
other patients were offered the test, subject to their
consent. Carotid artery stenosis was evaluated using
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previously defined criteria 20). In detail, peak systolic
velocity (PSV), end-diastolic velocity, and carotid index
(peak internal carotid artery velocity ÷ common carotid
artery velocity) were calculated, with PSV ＞ 130 cm/s
serving as criterion for ICA stenosis ＞ 50% and PSV
＞ 200 cm/s for stenosis ＞ 70%, respectively, according
to previously validated criteria 21). Stenosis ＞ 50% in
the presence of symptoms or ＞ 70% in asymptomatic
patients was considered clinically significant 22, 23).
Patients were excluded from the study if they had a
history of cancer, atrial fibrillation (or evidence of
intermittent atrial fibrillation), hemorrhagic stroke,
or if they had undergone carotid endarterectomy.
Patients with significant carotid stenosis (cases) were
matched to those without significant disease (controls)
in terms of age. Controls therefore consisted of
unselected consecutive adults admitted, for any reason, to our ward and for which carotid ultrasound
(performed for a medical indication or upon their consent) did not reveal significant carotid artery disease,
as previously specified. Demographic characteristics,
major modifiable risk factors for cerebrovascular disease (smoking, hypertension, diabetes, dyslipidemia),
history of cerebrovascular disease (ischemic strokes
and/or transient ischemic attacks, TIA), cardiovascular
disease and other comorbidities, as well as the use of
aspirin or any other anti-thrombotic therapy were
recorded for both cases and controls. Ischemic cerebrovascular disease was assessed using clinical and
radiologic (computerized tomography and/or magnetic
resonance imaging) data, as appropriate and patients
were classified according to the TOAST diagnostic
system 24). Risk factors for cerebrovascular disease were
assessed according to standard definitions 25). Main
characteristics of cases and controls are shown in
Table 1.
Peripheral blood was collected in EDTA anticoagulated tubes. Genomic DNA was processed with
proteinase K, followed by phenol extraction and ethanol precipitation, and was resuspended in 50 μL TE
buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0).
DNA purity was assessed measuring the A 260/A 280
ratio with a UV/VIS spectrophotometer.
Screening for allelic polymorphisms was performed using a previously described polymerase chain
reaction- restriction fragment length polymorphism
(PCR-RFLP) approach 15). Briefly, a 588-base pair
DNA fragment containing both polymorphic sites
(T280M and V249I) was initially amplified using the
primers and PCR conditions shown in Table 2. Assays
were performed by adding 100 ng genomic DNA to a
reaction mixture containing 1X PCR buffer, 250 μM
dNTPs, 2.0 mM MgCl 2, 0.2 mM of each primer and
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Table 1. Main characteristics of the study population
Carotid atherosclerosis
n = 150

Controls
n = 151

76.4 (9.4)
74 (49.3)
84 (56)
99 (66)
58 (38.7)
99 (66)
70 (46.7)
43 (28.7)
105 (70)

76.7 (9.6)
59 (39.1)
58 (38.4)
63 (41.7)
38 (25.2)
66 (43.7)
46 (30.5)
33 (21.9)
80 (53)

NS
NS
0.002
＜ 0.001
0.012
＜ 0.001
0.004
NS
0.002

64 (61)
20 (19)
9 (8.6)
12 (11.4)

9 (11.3)
34 (42.5)
18 (22.5)
19 (23.8)

＜ 0.001

89 (59.3)
23 (15.4)
38 (25.3)

104 (68.9)
27 (17.9)
20 (13.2)

Mean age (SD)
Male sex (%)
Smokers (%)
Hypertension (%)
Diabetes (%)
Dyslipidemia† (%)
Statin use
Aspirin use
Admission due to stroke/TIA
Stroke Classification§
Large vessel disease
Small vessel disease
TIA
Undetermined etiology
Previous ischemic events
None
One
Multiple

p

0.029

†

Presence of one of the following: pharmacological treatment, total serum cholesterol ＞ 6.2 mmol/L, LDLcholesterol ＞ 4.1 mmol/L.
§
According to the TOAST classification (24). Cardioembolic and strokes of other determined etiology were
excluded from the study and TIA were analysed separately.
NS = Not significant

Table 2. Parameters of PCR-RFLP analysis for the detection of polymorphisms of the CX3CR1 fractalkine receptor gene
PCR

Primer sequence

Conditions

F-CCGAGGTCCTTCAGGAAATCT
R-TCAGCATCAGGTTCAGGAACTC

RFLP

Polymorphism

Endonuclease

T280M
V249I

BsmbI
AclI

0.2 U Taq DNA polymerase (Life Technologies Ltd.,
UK) to a 25 μL total reaction volume. The PCR
products underwent RFLP analysis with restriction
endonucleases, conditions and bands (obtained following electrophoresis on 2% agarose gel) shown in
Table 2.
PCR-RFLP results were confirmed by DNA
sequencing of randomly selected samples (1 out of 5)
from all variants (homozygous for each genotype and
heterozygous) with an ABI 377 automated sequencer
(PE Applied Biosystems, Warrington, UK) using the

94℃ 3 min
94℃ 30 sec
52℃ 40 sec
72℃ 55 sec
72℃ 10 min

Product size (bp)
588

35 cycles

55℃ for 3 hours
37℃ for 3 hours

Wild-type
75, 216, 297
383, 205

Mutant
216, 372
588

same primers and fluorescent DNA capillary electrophoresis.
Data were analyzed using SPSS for Windows,
release 11.0.1 (SPSS, Chicago, IL, USA). To determine whether the distribution of each polymorphic
genotype fulfilled the Hardy-Weinberg equilibrium,
the χ2 test was used to compare the observed number
of subjects with the expected number.
Defining the homozygous phenotype for the
dominant allele as the reference group, the odds ratio
(with 95% confidence interval) for atheromatous dis-
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Table 3. Genotype combinations among the 301 subjects of
the study
V249I status
249V/V
249V/I
249I/I

T280M status
280T/T

280T/M

280M/M

139
58
2

14
64
11

2
1
10

p ＜ 0.001

ease was calculated for each polymorphism. Using
logistic regression analysis, the association of each polymorphism with atheromatous disease was adjusted for
age, gender, smoking status, diabetes mellitus, hypertension, dyslipidemia, and use of statins and aspirin.
To assess the independent role of 280M and 249I
mutants in stroke, we constructed a separate logistic
regression model which included the parameters listed
above, as well as the presence of atheromatous disease,
stroke type 24) and number of previous cerebrovascular
events (ischemic stroke and/or TIA). Using genotype
prevalence data from a similar population 13) we estimated that our sample gave 80% power to detect at
least a 2-fold increase of OR with a probability of
Type Ⅰ error a = 0.05. Continuous variables (i.e. age)
were examined using one-way analysis of variance.
Variables distributed in non-parametric fashion were
examined using the Mann-Whitney U or the KruskalWallis test, as appropriate. Normality was tested using
the Kolmogorov-Smirnov test.
Approval to conduct this research was obtained
from the Ethics Committee of Sotiria Hospital.
Results
We examined the prevalence of T280M and
V249I polymorphisms of the CX3CR1 fractalkine
receptor gene in 150 patients with clinically significant
carotid atheromatous disease and 151 age-matched
controls. Genotype distributions of both polymorphisms were compatible with the Hardy-Weinberg
hypothesis (Table 3). The allelic frequency of the
M280 mutant was lower among patients with clinically significant carotid atheromatous disease than
in age-matched controls (0.15 versus 0.23, adjusted
odds ratio 0.47, 95% confidence interval 0.30−0.74;
p = 0.008). Allelic and genotypic frequencies are shown
in Table 4. The odds ratio for carotid atherosclerosis
among carriers of the M280 allele was 0.34 (95% CI
0.20−0.60; p ＜ 0.001), after adjusting for age, gender,
smoking status, diabetes mellitus, hypertension, dyslipidemia, and use of statins and aspirin. The I249
mutant allele was also under-represented among

607

patients with carotid atherosclerosis (compared with
the control group) but this difference did not reach
statistical significance (Table 4). In multivariate analysis, absence of the M280 allele was the strongest factor
independently associated with carotid atheromatous
disease (OR 3.70, 95% CI 1.92−7.14; p = 0.001), its
effect being stronger than that of hypertension, dyslipidemia, diabetes and cigarette smoking, which were all
also independent risk factors for atheromatous disease
(Table 5).
One hundred and eighty-five study patients were
admitted to the hospital due to an ischemic cerebrovascular attack (stroke or TIA, Table 1). In multivariate analysis, T280M and V249I polymorphisms were
not associated with ischemic cerebrovascular attack,
whereas carotid atheromatous disease (OR 1.42, 95%
CI 1.30−1.56), a history of previous ischemic event
(OR 6.27, 95% CI 3.3−11.92), age (OR 1.04, 95% CI
1.01−1.07), hypertension (OR 1.39, 95% CI 1.29−
1.50), diabetes (OR 1.1, 95% CI 1.02−1.21), hyperlipidemia (OR 2.21, 95% CI 1.24−3.93) and cigarette
smoking (OR 1.31, 95% CI 1.22−1.37) were all independently associated with admission due to stroke/
TIA. When the 73 episodes of the stroke subtype (large
vessel disease) associated with carotid artery atherosclerosis 24) were analyzed separately, similar results
were obtained; neither T280M nor V249I polymorphisms were independently associated with admission
due to this type of ischemic stroke (data not shown).
Discussion
In this study, we found a significantly lower prevalence of the M280 mutant allele of the CX3CR1 gene
among patients with carotid atheromatous disease than
in age-matched controls without clinically significant
carotid atherosclerosis. The association between the
M280 allele and carotid artery atherosclerosis was
independent of the “conventional” risk factors for vascular disease. Furthermore, in multivariate analysis,
this polymorphism exerted the strongest effect on the
prevalence of carotid atherosclerosis in our cohort:
absence of M280 was associated with an almost 4-fold
risk for carotid atherosclerosis, which was higher than
the risk individually conferred by any of the “conventional” vascular risk factors (Table 5). In contrast, the
other known polymorphism on the CX3CR1 gene
(V249I) examined in this study did not correlate with
the presence of carotid atheromatous disease.
Our results are in agreement with those from
limited existing studies, concurring with an inverse
association between the 280M allele and carotid artery
atheromatous disease 16), perhaps due to decreased
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Table 4. Allelic and genotypic prevalence for CX3CR1 gene polymorphisms
Polymorphism
T280M
T/T
T/M
M/M
M280 carriers
T allele frequency
M allele frequency
V249I
V/V
V/I
I/I
I249 carriers
V allele frequency
I allele frequency

Carotid atherosclerosis
n = 150 (%)

Controls
n = 151 (%)

Odds ratio
(95% CI)

112 (74.7)
31 (20.7)
7 (4.6)
38 (25.3)
0.85
0.15

87 (57.6)
58 (38.4)
6 (4)
64 (42.4)
0.77
0.23

1
0.42 (0.25−0.70)
0.91 (0.29−2.79)
0.34 (0.20−0.60)†
1
0.47 (0.30−0.74)†

82 (54.7)
59 (39.3)
9 (6)
68 (45.3)
0.74
0.26

73 (48.3)
64 (42.4)
14 (9.3)
78 (51.7)
0.7
0.3

1
0.82 (0.51−1.32)
0.57 (0.23−1.4)
0.64 (0.35−1.18)†
1
0.71 (0.58−1.09)†

p value

p ＜ 0.001
p = 0.002
p = 0.01

NS
NS
NS

†

adjusted for age, gender, smoking status, diabetes mellitus, hypertension, dyslipidemia, and use of statins and aspirin.
CI = Confidence interval; NS = Not significant.

Table 5. Multivariate analysis of factors associated with carotid
atheromatous disease
Correlation Coefficient
(95% CI)
Age
Male sex
Cigarette smoking
Hypertension
Diabetes
Dyslipidemia
Absence of M280 allele
I249 allele

1.02 (0.99−1.04)
1.58 (0.93−2.70)
2.29 (1.34−3.92)
2.94 (1.76−4.92)
2.08 (1.20−3.63)
2.77 (1.65−4.66)
3.70 (1.92−7.14)
0.69 (0.32−1.21)

intima-media thickness 17). Although the exact functional role of the fractalkine receptor has not been
fully elucidated, it has been proposed that the presence of the 280M allele impairs the ability of the
molecule to participate in the inflammatory process
underlying the development of atherosclerosis; this is
supported by the reduced intima-media thickness and
the decreased adhesive function, signaling and chemotaxis of leukocytes from subjects homozygous for the
280M allele 11, 17). The role of the V249I polymorphism,
although in linkage disequilibrium with T280M, is
less clear: we could not find any association between
this polymorphism and carotid atheromatous disease,
which is also consistent with previous reports 16, 17),
although in one of those studies the 249I allele was
associated with the consistency of the plaques, but not

with the overall prevalence of carotid disease 16).
Despite the protective role of the 280M allele
against carotid atherosclerosis, a negative association
between this allele and ischemic cerebrovascular disease
has not been detected: one case-control study found a
positive risk of brain infarction among homozygotes
for the 280M allele 18), whereas another study did not
detect any association 19). Our study was not designed
to specifically address this issue, but we note that, in
contrast with carotid atherosclerosis and the major
vascular risk factors, CX3CR1 genotypes were not
independently associated with admission due to an
ischemic cerebrovascular event. This was also the case
when the stroke category (large vessel disease) associated with carotid artery occlusive disease was analyzed
separately; no such analysis has been performed in
previous relevant studies.
The discrepancy of 280M allelotype associations
between carotid atherosclerosis and ischemic strokes is
difficult to explain in the absence of prospective studies. There is good experimental evidence of the role of
the fractalkine receptor during the atherogenetic process 8, 26) and that the rare homozygosity for 280M/
249I confers defective adhesive function and chemotaxis 11). Notably, however, vascular atherosclerosis leading to ischemic stroke is a multifactorial process in
which several parameters and risk factors are implicated 2). This can mask the effect of a rare condition,
such as 280M/249I homozygosity, in multivariate
analysis. In this regard, it is interesting that the risk
of brain infarction previously associated with homozy-
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gosity for rare CX3CR1 alleles was more marked in
patients with no previous cardiovascular events 18),
although that analysis was also restricted by the small
number of homozygous patients. On the other hand,
recent data suggests that CX3CR1 deficiency has a
favorable effect on ischemic damage and inflammation 27), which is in contrast with the results from
genetic case-control studies 18, 19). In our study, we
noted an observed number of 280M homozygosity
slightly higher than expected among carotid atherosclerosis patients, given the described protective association of the 280M allele presence (Table 4). This
was likely due to the very small number of homozygous cases, which did not allow for safe conclusions;
however, the role of the rare 280M homozygosity
needs further clarification at both functional and epidemiologic levels. Given that polymorphisms on other
genes, such as MMP and TIMP, have recently also been
implicated in atherosclerosis via regulation of carotid
artery intima-media thickness 28), it is apparent that
the exact role of the CX3CR1 gene and its polymorphisms in carotid atherosclerosis and progression to
ischemic strokes has not yet been elucidated.
There are several limitations of our study. Its
cross-sectional, non-randomised nature allows association, but not necessarily causation to be assumed.
Selection bias is also inherent: patients who were not
admitted due to stroke underwent carotid examination voluntarily in contrast with stroke sufferers for
whom the test was part of the work-up. Related to
this, the rate of admissions due to stroke was (expectedly) particularly high among patients with carotid
atherosclerosis. Efforts to minimize bias included
matching cases to controls in terms of age, exclusion
of patients with hemorrhagic or cardioembolic strokes
and examining the role of CX3CR1 polymorphisms
separately in the stroke subtype associated with carotid
atherosclerosis. Data from CT-angiogram or surgery
were not included in the analysis since they were not
available for all patients and could not be obviously
performed in controls. Carotid disease was assessed
with Doppler ultrasound. This test is subject to interoperator variations, the effect of which seems to have
been minimized with the development of newer techniques, machines and criteria 21, 29). Finally, unidentified parameters might have interfered with our results:
transcranial Doppler was not used and the effect of
intracranial atherosclerosis could not be estimated,
similar to high-sensitivity C-reactive protein, to reflect
the degree of inflammation in atheromatous plaques.
Despite the above limitations, our study provides
further evidence that the 280M allele has a strong protective effect against carotid atherosclerosis, which is
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independent of the major “conventional” risk factors
for cerebrovascular disease. Whether this is translated
to an effect on the prevalence of ischemic cerebrovascular attacks needs to be addressed with a prospective,
massive-scale population study. Validation of such
hypothesis and elucidation of its mechanism will have
obvious benefits, offering therapeutic perspectives for
genetic modification, as well as incorporating the evaluation of genetic parameters into risk assessment for
ischemic stroke, to guide therapeutic decisions appropriately.
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